Back to Authors

Chiappella, Annalisa

https://orcid.org/0000-0002-2977-0098

A5054623894 | I4210156707

Mayo Clinic

Fondazione IRCCS Istituto Nazionale dei Tumori

Citations 16

Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8600-TPS8600

10.1200/jco.2015.33.15_suppl.tps8600

Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7538-7538

10.1200/jco.2016.34.15_suppl.7538

Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7562-7562

10.1200/jco.2018.36.15_suppl.7562

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7548-7548

10.1200/jco.2018.36.15_suppl.7548

ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 419-419

10.1002/hon.2440

ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma

Future Oncology | April 18, 2016 | Volume: 12 | Issue: 13 | Pages: 1553-1563

10.2217/fon-2016-0130 | PMID 27089170